Providers

This new report helps clarify the ways in which the disease—and its treatment—affects the lives of children.

This analysis found the complex decision-making process of lung cancer screening among eligible individuals is infused with 3 principal themes that may influence how primary care physicians approach patients with comorbidities.

“Policies that require and reimburse universal mental health screening at postpartum visits, ensure connection to care, reduce gaps in postpartum insurance coverage, and require clinician training in culturally responsive resources could improve equity of postpartum depression diagnoses and care in the US,” study authors wrote.

The first-in-class oral factor D inhibitor danicopan (Voydeya) has been approved for the management of extravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria (PNH).

Treatment with R-GemOx was associated with significant health care resource utilization, high costs surrounding treatment, and low overall survival in elderly patients with diffuse large B-cell lymphoma (DLBCL).

Despite being used for decades, there continues to be emerging data on interferons and how they should be used in patients with myeloproliferative neoplasms (MPNs), explains Raajit Rampal, MD, PhD, hematologic oncologist, associate attending physician, Memorial Sloan Kettering Cancer Center.

Part 1 of a 3-part feature series on the history, evolution, and current state of LGBTQ+ health care is focused on the unique needs and journey of transgender patients in the US health system, as well as the policies and social influences that have shaped their access to care.

An artificial intelligence (AI) mode was more accurate in assessing patient risks for skin cancer through the analysis of 2D facial images compared with more traditional risk-factor screening.

An abstract presented at the 2024 Society of Gynecologic Oncology Annual Meeting on Women’s Cancer explored patient-reported health-related quality of life (HRQOL) among patients treated with mirvetuximab soravtansine compared with standard chemotherapy.

The majority of studies evaluating biosimilar-to-biosimilar switching were for rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, and ankylosing spondylitis.

A population-based cohort study out of Norway has found that older men have a higher risk of developing second primary invasive melanoma following an initial primary melanoma, suggesting the benefits of increased surveillance in these patients.

Patrick Vermersch, MD, PhD, University of Lille, France details the adverse events observed in the frexalimab trials and the next steps necessary to establish frexalimab as a standard of care in multiple sclerosis (MS) in the third and final part of an interview.

This analysis included 119 patients with advanced lung cancer, who were evaluated on 3 facets of physical activity over 14 days of using the amuelink wearable device from Sony: metabolic equivalent tasks, distance walked, and steps taken.

These insights, explain the researchers of the study, complement observational studies, which have previously indicated a causal relationship between the 2 diseases.

Clinician and patient interviews indicated satisfaction with the items presented to help describe patient symptoms with different lymphomas.

For most patients younger than age 60 with polycythemia vera (PV) who are not considered high risk, cytoreductive therapies are withheld despite being highly effective.

Investigators used the Functional Assessment of Cancer Therapy-General General Physical Wellbeing Scale to collect data on patient-reported treatment-related adverse effects, to provide clinicians guidance on predicting risk of early treatment discontinuation among ECOG-ACRIN E1A11 trial participants.

Results from a retrospective cohort study analyzing patients with breast cancer bolster reports of an association between radiation therapy and subsequent risks of skin cancers.

The FDA issued complete response letters (CRLs) for the biologics license application for odronextamab in relapsed/refractory (R/R) follicular lymphoma and in R/R diffuse large B-cell lymphoma (DLBCL).

For Lp(a) Awareness Day, Mary McGowan, MD, FNLA, chief medical officer of the Family Heart Foundation, highlights how most people with elevated Lp(a) are completely unaware that they have this increased risk and calls for increased testing.

The Center on Health Equity and Access covered disparities in hypertension, diabetic eye health, and hidradenitis suppurativa, along with the proposed legislation banning diversity, equity, and inclusion efforts in Alabama schools and the consequences in sickle cell care from the CDC guideline for opioid prescriptions.

Interferons have been a major treatment for myeloproliferative neoplasms (MPNs) for decades, but emerging therapies are expanding the treatment armamentarium, explained Raajit Rampal, MD, PhD, of Memorial Sloan Kettering Cancer Center.

Machine learning models have potential for early identification of patients with metabolic dysfunction-associated steatotic liver disease (MASLD) who are at risk of hepatocellular carcinoma.

A history of depression was the most predictive factor for developing persistent joint pain among patients with psoriatic arthritis.

Mirvetuximab soravtansine-gynx (Elahere) received full FDA approval for the treatment of folate receptor alpha–positive (FRα+), platinum-resistant ovarian cancer (PROC) based on findings from the confirmatory phase 3 MIRASOL trial.

Al Benson, MD, FACP, FACCC, FASCO, medical oncologist at Northwestern University Feinberg School of Medicine and associate director of the Robert E. Tillery Comprehensive Cancer Center, discussed findings from a national survey assessing barriers to comprehensive cancer care delivery.

A retrospective, qualitative cohort study concludes that patients with sickle cell disease (SCD) may have been negatively impacted by the 2016 CDC guidance.

This longitudinal observational study found higher team satisfaction with workload to be significantly associated with lower primary care physician turnover.

Patients with colorectal cancer (CRC) and spousal caregivers were found to benefit from a couple-based posttraumatic growth intervention visits in a randomized controlled study.

Once-daily aprocitentan (Tryvio) is the first and only FDA-approved endothelin receptor antagonist for treating high blood pressure that remains uncontrolled despite other antihypertensive treatments.